semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 17.0-80.0,  Breast Neoplasms Tumor diameter ≤3 cm Tumor from the papilla>2cm Low grade ductal carcinoma in situ Candidate for breast-conserving surgery Must have undergone lumpectomy with negative margins or minimal margin involvement Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection No evidence of metastatic disease Informed consent  No informed consent Tumor size > 3 cm Tumor from the papilla≤2cm Intermediate or high grade ductal carcinoma in situ Invasive carcinoma No indication for a boost
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HER2/Neu Negative Progesterone Receptor Negative Progesterone Receptor Positive Stage IV Breast Cancer AJCC v6 and v7 Capable and willing to provide informed consent Women must not be pregnant or breast-feeding. All females of childbearing potential must have a blood test or urine study within 7 days prior to FES PET/CT scan and [18F]-fluorodeoxyglucose (FDG)-PET/CT scan to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following Has not undergone a hysterectomy or bilateral oophorectomy or Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study Patient is a postmenopausal woman, man, or premenopausal woman for whom standard endocrine therapy alone (tamoxifen, aromatase inhibitor [AI], with or without ovarian suppression or fulvestrant) is planned after FES-PET/CT is completed Medically stable as judged by patient's physician Life expectancy must be estimated by patient's physician at > 6 months Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years) Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women, aged 18 years and older Able to give informed consent herself World Health Organization (WHO) performance score ≤ 2 Biopsy proven cT1-2 N0-2 MX invasive breast cancer with a size of ≤ 3.0 cm Histological type of tumor: invasive ductal carcinoma (IDC), not otherwise specified (NOS) or no special type (NST) The target breast fits in the cup of the dedicated MR-HIFU breast system Patient weight is limited to ≤ 90 kg, because of restrictions to the HIFU table top. Additional based on DCE-MRI findings The distance of the tumor, including a 5 mm margin around the tumor, from the skin, nipple and pectoral wall is at least 1.0 cm measured on MRI The tumor is located within the reach of the HIFU beam produced by the transducers in the HIFU breast system  Prior treatment with: neo-adjuvant systemic therapy in the past 3 months or radiotherapy or thermal therapy or surgery of any kind in the targeted breast Contraindications to MR imaging according to the hospital guidelines (e.g. pacemaker in situ, severe claustrophobia, big metal implants, body size incompatible with MR bore) Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, kidney disease (e.g. nephrogenic systemic fibrosis, nephrogenic fibrosing dermopathy) and/or renal failure (GFR < 30 ml/min/1,73m2) Contra-indications for procedural sedation analgesia with Propofol and Esketamine or Propofol and Remifentanil Extensive intraductal components in the lesion determined by biopsy Scar tissue or surgical clips in the HIFU beam path Inability to lie in prone position Pregnancy or lactation Communication barrier with patient. The following groups of patients will be excluded because the risk of adjuvant over or undertreatment due to performing the Bloom and Richardson (B&R) grading on the tumor biopsy is considered to high
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  HER2 Positive Metastatic Breast Cancer Aged ≥18 and ≤70 years ECOG performance status of 0 to 1 Life expectancy of more than 12 weeks At least one measurable lesion exists.(RECIST 1.1) Histologically or cytologic confirmed HER2 positive advanced breast cancer which failed prior therapies Required laboratory values including following parameters: ANC: ≥ 1.5 x 10^9/L;Platelet count: ≥ 100 x 10^9/L;Hemoglobin: ≥ 9.0 g/dL;Total bilirubin: ≤ 1.5 x upper limit of normal (ULN);ALT and AST: ≤ 1.5 x ULN;BUN and creatine clearance rate: ≥ 50 mL/min;LVEF: ≥ 50%;QTcF: < 470 ms for female and < 450 ms for male Signed informed consent  Received previous therapy with lapatinib, neratinib, pyrotinib or any other HER2 directe tyrosine kinase inhibitor Received previous therapy with capecitabine within 3 months
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Breast Cancer Women aged 50 and over initially diagnosed with breast cancer by histological tissue diagnosis in 2003 or later. 2. Currently Stage IV (metastatic) breast cancer on the basis of definitive imaging or biopsy with stable disease (scans within the past 2 months). 3. ECOG (Eastern Cooperative Group) Performance Score of 0 or 1. 4. Able to participate occasionally in mildly strenuous physical effort. 5. Able to read, speak, and write in English or ability to provide consent or understand questionnaires. 6. Able to be accompanied by their spouse or significant other partner/friend (spouse, significant other, partner, or friend. 7. Able to travel to the retreat site. 8. Must be right handed. 9. Patients must have had a contrast-enhanced computerized tomographic (CT) scan of the chest and abdomen within 2 months of study entry and be willing to have a follow up scan within 2 months of the completion of the retreat. 10. (CAREGIVERS ONLY) Must be primary caregiver of the patient. 11. (CAREGIVERS ONLY) Able to read, speak, and write in English. 12. (CAREGIVERS ONLY) Able to attend the last two days of the retreat with patient  Significant co-morbidities (e.g., diabetes, cardiac disease, or other condition that in the opinion of the primary physician or investigators would limit participation in the intervention groups) that would preclude study participation. 2. Evidence of disease progression that would necessitate a treatment in the next 2 weeks. 3. Need for intravenous therapy more frequently than every 3 weeks or inability to time intravenous therapy treatment before and after the study. 4. Currently in treatment for a major psychiatric disorder 5. Clinical history of severe psychiatric disorders. 6. Currently receiving chemotherapy. 7. (CAREGIVERS ONLY) Must be an adult (>=18 years old)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Hormone Receptor Positive Tumor Early-Stage Breast Carcinoma Have postmenopausal status Adenocarcinoma of the breast Breast tumor ≥1 centimeter (cm) in diameter, HR+, HER2- Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy Primary breast cancer that is suitable for baseline core biopsy Have adequate organ function  Bilateral invasive breast cancer Metastatic breast cancer (local spread to axillary lymph nodes is permitted) Inflammatory breast cancer Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated Prior radiotherapy to the ipsilateral chest wall for any malignancy Prior anti-estrogen therapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Estrogen Receptor Negative HER2/Neu Negative Invasive Breast Carcinoma Progesterone Receptor Negative Stage II Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Triple-Negative Breast Carcinoma FOR AND (STEP 0) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 2 weeks prior to screening Female and male patients must have histologically confirmed invasive breast cancer that meets the following Clinical stage II-III (American Joint Committee on Cancer [AJCC] 7th edition) at diagnosis, based on initial evaluation by clinical examination and/or breast imaging; no metastatic disease allowed and PR should meet one of the following =< 10% cells stain positive, with weak intensity score (equivalent to Allred score =< 3) =< 1% cells stain positive, with weak or intermediate intensity score (equivalent to Allred score =< 3) HER2 negative (not eligible for anti-HER2 therapy) will be defined as Immunohistochemistry (IHC) 0, 1+ without in situ hybridization (ISH) HER2/neu chromosome 17 ratio OR
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Chemotherapy, Adjuvant Women with histologically confirmed breast cancer who had undergone radical mastectomy or breast-conserving surgery in addition to full ipsilateral axillary lymph node dissection Lymph node-positive disease with less than 10 involved axillary lymph nodes Surgery performed not more than 5 weeks before randomization ECOG performance status 0 Absolute neutrophil count ≥ 2,000/mm³ WBC ≥ 3,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 times upper limit of normal (ULN) AST and ALT ≤ 1.5 times ULN Postoperative regional radiotherapy limited to the remaining breast admitted for patients who received breast-conserving surgery  Prior or concurrent ipsilateral or contralateral invasive breast carcinoma within the last 10 years Metastatic disease, including metastasis in the ipsilateral supraclavicular lymph nodes Prior chemotherapy or prior cytotoxic regimens or prior hormonal therapy Pregnant or nursing Other serious medical illness requiring medication, uncontrolled infections Other malignancy except adequately treated, cone-biopsied in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin Recent myocardial infarction, congestive heart failure, or serious arrhythmia
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Pancreatic Cancer Secondary Malignant Neoplasm of Lymph Node Benign Neoplasm of Lymph Nodes Benign Pancreatic Tumors Patients diagnosed with solid pancreatic tumor masses, with cytological / histo-logical confirmation Patients with or without suspected lymph node involvement are eligible Age 18 to 90 years old, men or women Signed informed consent for EG-EUS, CE-EUS and FNA biopsy  Prior surgical treatment with curative intent or chemo-radiotherapy Patients diagnosed with mucin producing tumors, pancreatic cystic tumors, etc
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Cancer Female aged 18 years old; 2. Staging of Cancer: cT1-2N0-1M0; 3. Histological confirmed with unilateral invasive carcinoma (all pathological types are applicable); 4. Definite reports on ER/PR/Her2 receptor showing all ER/PR/Her2 negative (specific definitions: immunohistochemical detection of ER <10% tumor cells is defined as ER negative, PR <10% positive tumor cells is defined as PR-negative, Her2 is 0~1+ or 2+ but determined negative via FISH or CISH detected (no amplification) is defined as Her2 negative); 5. Newly diagnosed conditions allowing direct surgery without any absolute contraindication for surgery; 6. ECOG performance score is 0 or 1; 7. No mass or microscopic tumor residue after surgery resection; 8. Informed consent form signed. 9. Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study  Bilateral breast cancer; 2. Clinical or radiographic evidence of metastatic disease; 3. Widespread disease that cannot be incorporated by local excision through a single incision that achieves negative margins with a satisfactory cosmetic result; 4. Diffuse suspicious or malignant-appearing microcalcifications; 5. Positive pathologic margin; 6. Any of ER, PR or Her2 is positive; 7. Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone therapy; 8. Prior history of breast cancer or any other malignant disease (except for basal cell carcinoma and cervical carcinoma in situ); 9. Severe systemic disease and/or uncontrollable infection, unable to be enrolled in this study; 10. Known allergic to taxane and anthracycline agents; 11. Pregnant and breast-feeding women; 12. With mental illness and cognitive impairment, unable to understand trial protocol and side effects and complete trial protocol and follow-ups; 13. Without personal freedom and independent civil capacity
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Early-Stage Breast Carcinoma invasive mamma carcinoma as verified by core cut biopsy extensive ductal carcinoma in situ as verified by core cut biopsy (at least 5 cm or at least 2,5 cm and G3 grading) clinical stage tumor T1-T3 no signs of axillary lymph node metastasis on clinical examination including ultrasound examination no signs of distant metastatic disease male/ female patient in the age not less than 18 years Karnofsky performance status at least 70% or Eastern Cooperative Oncology Group (ECOG) score not higher than 1 written patient informed consent  suspect axillary lymph nodes on clinical/ultrasound examination positive fine-needle biopsy of axillary lymph nodes sentinel lymph node biopsy to be performed after neoadjuvant chemotherapy recurrence of a mamma carcinoma prior extensive surgery of breast or axilla inflammatory or extramammary breast cancer pregnancy contraindication to the radionuclide inability to understand the studies purpose inability to receive surgery
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Node-positive Breast Cancer Breast Adenocarcinoma Invasive Breast Carcinoma Lobular Breast Carcinoma In Situ Karnofsky performance status of 70-100% Histologic documentation of invasive adenocarcinoma of the breast One of the breast disease stages listed below Note: In the definitions below, definitive surgery is defined as the final surgery performed to obtain clear surgical margins Neoadjuvant chemotherapy was not administered ** If neoadjuvant chemotherapy was NOT administered, pathologic staging must be T1-3, N1-2a following definitive surgery Neoadjuvant chemotherapy was administered If prior to initiation of neoadjuvant chemotherapy clinical staging was T1-3, N0, pathologic staging must be T1-3, N1-2a following definitive surgery If prior to initiation of neoadjuvant chemotherapy clinical staging was T1-3, N1, pathologic staging must be T0-3, N0-2a following definitive surgery If prior to initiation of neoadjuvant chemotherapy there was cytologic or pathologic confirmation of axillary nodal involvement (per any of the listed below), pathologic staging must be T0-3, N0-2a following definitive surgery Positive fine-needle aspiration (FNA) (ie, demonstrating malignant cells)  Known definitive clinical or radiologic evidence of metastatic disease T4 tumors including inflammatory breast cancer Clinical nodal staging of N2 or N3 disease Pathologic nodal staging of N2b, N2c, or N3 disease Microscopic positive margins after definitive surgery * Note: Patients with microscopically focally positive margins following lumpectomy or mastectomy are not excluded if re-excision is not technically feasible and/or there is no benefit to further surgery based on the extent and location of the positive margin Any history, not including the index cancer, of ipsilateral or contralateral invasive breast cancer or ipsilateral or contralateral DCIS treated with radiation therapy (RT) * Note: Patients with synchronous or previous ipsilateral LCIS are eligible Any radiation therapy (RT) for the currently diagnosed breast cancer prior to study enrollment History of ipsilateral or contralateral breast or thoracic RT for any condition History of ipsilateral or contralateral axillary surgery for any condition History of lymphedema involving the ipsilateral or contralateral arm at present or at any time in the past